Login to Your Account



Noxxon Pharma Gets $50M For Spiegelmer Drug Development

By Cormac Sheridan


Wednesday, May 9, 2007
Noxxon Pharma AG added €37 million (US$50.3 million) to its coffers in a Series C round that will enable the company to take its two lead programs, NOX-E36 and NOX-A12, into development for lupus nephritis and diabetic retinopathy, respectively, through clinical proof of concept. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription